Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Hjardem E, Østergaard M, Pødenphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, Rødgaard A, Skøt J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML.
Hjardem E, et al. Among authors: hetland ml.
Ann Rheum Dis. 2007 Sep;66(9):1184-9. doi: 10.1136/ard.2006.054742. Epub 2007 Mar 27.
Ann Rheum Dis. 2007.
PMID: 17389656
Free PMC article.